

MSN Labs launches VIGANEXT for epilepsy

17 November 2021 | News

Oral solution vigabatrin is recommended as the first-line therapy for infantile spasm, a form of epilepsy



MSN Labs has announced the launch of anti-epileptic and India's first generic vigabatrin powder for the oral solution under the brand name VIGANEXT.

Vigabatrin is recommended as the first-line therapy for infantile spasms, a form of epilepsy that affects 1 in 2,000 children. Previously, the availability of Vigabatrin was wholly dependent on grey market imports which were severely disrupted during the COVID-19 lockdowns. MSN Labs reached out to DCGI for necessary approval to serve epilepsy patients in India with an uninterrupted supply of affordable Vigabatrin.

A therapeutic equivalent, the drug approved by the Drugs Controller General of India (DCGI), is indicated for Infantile Spasms - monotherapy in infants one month to two years of age - and as adjunctive therapy for Refractory Complex Partial Seizures in patients two years of age and older who have responded inadequately to several alternative treatments.

VIGANEXT, available in 500 mg sachet with 30 sachets per pack, is manufactured at our state-of-the-art US FDA and EU approved finished dosages manufacturing campus at Hyderabad. Both BRIVANEXT & VIGANEXT are available in Pharmacies as affordable therapeutic options.